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ABSTRACT 
Background: There is currently no high grade evidence on which to base decisions about the 
frequency of intravenous cannula re-sites 
Objective: To assess the safety of changing peripheral venous cannulas when clinically 
indicated 
Design: Randomised controlled trial 
Setting: A tertiary referral hospital in Brisbane, Australia 
Participants: 206 hospitalised patients from surgical, medical and orthopaedic wards 
Interventions: Peripheral intravenous cannulas were re-sited only when complications 
occurred (intervention group) or every 3 days (control group). 
Main outcome measures: The primary endpoint was a composite measure of complications 
leading to an unplanned cannula removal, the secondary outcome was cost.  
Results: Forty six patients had unplanned removals in the intervention group compared with 
41 in the control group [relative risk 1.12, 95% confidence interval 0.81 to 1.55 (p = 0.286)]. 
Total duration of peripheral cannulation was similar in both groups (mean 123.3 hours in the 
intervention group and 125.9 hours in the control group: P = 0.82) but significantly more re-
sites occurred in the control group (167 in intervention group, 202 in the control group: p = 
0.022). Cost of cannula replacements in the intervention group was AUD$3,183.62 and in the 
control group AUD$3,837.56 (p = 0.006). After adjustment for other risk factors, frequency 
of cannulation [odds ratio (OR) 0.78. 95% confidence interval (CI) 0.27 – 0.22], total duration 
of cannulation (OR 1.01. CI 1.00 – 1.02) and irritability of IV medications other than 
antibiotics (OR 0.45, CI 0.21 – 0.97) were positively associated with unplanned cannula 
removal.   
Conclusion: Re-siting peripheral venous cannulas when clinically indicated compared with 
changing them routinely every 3 days does not lead to more complications and reduces costs.  
 
Keywords: Clinical trials; Cost and cost analysis; Infusions, intravenous  
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What is already known about this topic: 
 
• Peripheral intravenous cannulation is the most common invasive procedure amongst 
hospitalised patients 
• Each time the integrity of the skin is breached there is an opportunity for invasion by 
pathogenic organisms 
• Current guidelines/recommendations about how often peripheral intravenous 
cannulas should be re-sited has not been tested using an appropriately powered 
randomised controlled trial. 
 
What this paper adds: 
• Unplanned cannula removal rates are not affected by the length of time an individual 
cannula remains in situ 
• Frequency of re-sites and the total length of time the patient remains cannulated are 
independently associated with adverse outcomes 
• Costs are reduced when intravenous peripheral cannulas are re-sited when clinically 
indicated compared with re-siting every three days.  
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Introduction 
Among hospitalised patients, intravenous therapy is the most common invasive procedure. It 
is associated with a phlebitis rate of between 2.3% and 35% (Martinez et al., 1994, Tager et 
al., 1983, White, 2001) and an intravenous catheter related bacteraemia rate of approximately 
0.8% (Maki and Ringer, 1991). Current guidelines recommend that peripheral intravenous 
catheters should be re-sited every 72-96 hours to restrict infection potential (O'Grady et al., 
2002), and most hospitals follow this recommendation. However, recent observational studies 
have challenged the need for such frequent re-sites (Catney et al., 2001, Cornely et al., 2002, 
Homer and Holmes, 1998). In fact there is some evidence to suggest that the risk of infection 
may be higher with 3-day changes compared with longer dwell times because skin integrity is 
breached more often (Bregenzer et al., 1998).  
 
Most of the studies in this area to date have used retrospective or prospective observational 
designs. Our primary objective was to assess the safety of prolonging the time between 
intravenous cannula re-sites using more rigorous methods.  
 
Method 
Study population 
Human Research Ethics Committee gave approval to conduct the trial. Participants were 
eligible for the DRIP trial if they were inpatients at the Royal Brisbane and Royal Women's 
Hospital, were at least 18 years of age and expected to have a peripheral venous catheter 
indwelling for at least 4 days. The trial was controversial as it contravened existing 
guidelines, so we restricted entry to those who had their cannula inserted by a nurse from the 
IV Therapy Team. This enabled us to standardise insertion methods and closely monitor 
insertion sites. We excluded patients with an existing bloodstream infection and those 
receiving immunosupressive treatment. At the time of peripheral catheter insertion, all 
potentially eligible participants were given a trial information leaflet outlining the study. 
Within 72 hours they were asked for their written consent.  
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Intervention 
The intervention group had their peripheral venous catheter re-sited when clinically indicated 
by either phlebitis, local infection, bacteraemia, infiltration or blockage. The control group 
had a new peripheral venous catheter re-located to a different site every 3 days (or if clinically 
indicated if less than 3 days).  A member of the IV Unit was responsible for inserting all 
initial and replacement catheters. Choice of catheter type and gauge was at the discretion of 
the nurse inserting the catheter. Catheter insertion sites were inspected daily by a nurse from 
the IV Unit and by ward nurses according to usual practice as part of their usual practice (eg 
during 'routine observations' and when IV solutions were changed or when medications 
added). For all study participants the following characteristics were collected at baseline: age, 
sex, diagnosis at hospital admission, ward in which the patient was being treated, severity of 
risk of infection based on Tagar’s classifications (Tager et al., 1983), any co-morbid medical 
conditions, whether or not the patient was immunosupressed (defined as an absolute leucocyte 
count of less than 1,000/uL on the day of insertion, (Cornely et al., 2002) presence of 
infection at any site (as noted in the medical record), type of surgery (if applicable), antibiotic 
therapy, presence of any other vascular device or presence of an indwelling urinary catheter. 
At the time of the original cannula insertion and for each re-site the following information 
was collected: type of infusate and any additives, names of all medications injected into the 
IV set, type and size of catheter used and insertion site. All medications and infusates were 
graded on an ‘irritability scale’ (Catney et al., 2001). The scale, which was modified for the 
study by our hospital pharmacist to include medications received by patients during the study, 
ranged between 1 (least irritable) and 4 (most irritibale). If the patient was receiving more 
than one additive, we recorded the one with the highest irritability score. Vein quality was 
classified by IV Unit staff on a  6-point scale from ‘extremely limited’ to ‘good’ in line with 
their usual practice. Participants were monitored for the total infusion period and followed 
until 48 hours after catheter removal or until discharge. Times and dates of insertion and 
removal were recorded. Unexpected serious adverse events occuring during the period of 
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hospitalisation were notified to the Chief Investigator within 24 hours and a report prepared 
for the Human Research Ethics Committee.  
Primary outcome measure 
We used a composite measure of any unplanned reason for cannula removal. That is, if the 
cannula was removed for any of the following reasons, the patient was considered to have had 
an ‘unplanned’ cannula removal i) leakage around the cannula; ii) infiltration (defined as 
permeation of non-vesicant IV fluid into the interstial compartment, causing swelling of the 
tissue around the site of the catheter); iii) erythema; iv) occlusion/blockage; v) pain; vi) 
accidental removal; vii) local infection at the site of the catheter (defined as erythema with 
cellulitis at the site or pus); viii) phlebitis (defined as the presence of  two or more of the 
following: pain, tenderness, warmth, erythema, swelling, and a palpable cord (Bregenzer et 
al., 1998, Maki and Ringer, 1991, Monreal et al., 1999) during the course of the infusion and 
up to 48 hours after peripheral venous catheter removal) or  ix) catheter-related blood stream 
infection (based on the isolation of a phenotypically identical organism from a catheter 
segment and a blood culture (Cornely et al., 2002)).  
Secondary outcome Measure 
Cost 
Cost was calculated in two ways, costs associated with cannulas inserted for the 
administration of intermittent IV medication and cost associated with IV cannulas inserted for 
continuous infusion. For the first group, which we estimated to be 25% of the population we 
calculated a total cost of AUD $14.26. This included 20 minutes nursing time @ AUD $9.00 
(locating patient, preparation and insertion),  a cannula @ $1.20AUD, a 3 way tap @ AUD 
$2.15, a basic dressing pack @ AUD $0.54c, a syringe @ AUD $0.13c, transparent adhesive 
dressing @ AUD $0.74c, skin disinfection AUD $0.05c and local anaesthetic AUD $0.34c 
per insertion. For patients receiving a continuous infusion we calculated a total cost of AUD 
$21.26 per insertion. This included all the above costs plus the additional cost of replacing all 
associated lines, solutions and additives which are discarded when a cannula is changed (ie 
 7
intravenous administration set @ AUD $5.50 and 1 litre Sodium Chloride 0.09% @ AUD 
$1.50. 
Sample size 
We based our sample size on an estimated 40% rate of unplanned cannula removals (estimate 
from the IV Unit leader). We calculated that a sample size of  105 in each arm of the study 
would be needed to detect a 50% reduction in the primary outcome measure  (two tailed, α = 
0.05, power 80%).   
 
Randomisation and blinding 
Randomisation was by a computer generated random number list, stratified by oncology 
status. Allocation to the control or treatment group was made by phoning a person who was 
independent of the recruitment process and blind to baseline clinical data. The person 
assessing the outcome (a nurse from the IV Unit) was not blinded to the study group but was 
unassociated with the the study. 
 
Microbial analysis 
In line with hospital policy, microbiological evaluation of catheters was not undertaken 
routinely, due to the extremely rare incidence of peripheral vein catheter-related blood stream 
infection (Lai, 1998, Tager et al., 1983) and the cost associated with routine culture. 
However, if a catheter was removed for phlebitis or a suspected catheter-related infection and 
there was pus at the site, staff were asked to take a skin culture around the puncture site and 
cut a 3cm segment from the catheter tip. Specimens collected according to hospital protcol 
were to be forwarded to the laboratory for standard testing,  
 
Statistical analysis 
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We conducted an intention to treat analysis. We analysed the primary outcome using the 2-
sided Fisher’s Exact test and results are presented as relative risks with 95% confidence 
intervals. A Student’s t-test comparison of intervention versus control was used for the 
secondary outcome. In further analyses, results from all participants were combined and 
divided into two groups, those requiring an unplanned re-site and those not requiring an 
unplanned re-site, to test for risk factors associated with unplanned cannula removal. 
Categories of  some variables (eg site of cannula insertion, vein quality and level of irritability 
of solutions and medications) contained small numbers and were collapsed into 2 categories 
for the analysis. The two groups were first compared using univariate statistical tests, t-test, χ2 
test or Fisher’s exact test when applicable. Following this, logistic regression analysis was 
used to determine the strength of association of each variable after adjusting for the rest of the 
variables. Only those variables that were significant in the univariate analysis, and were felt to 
be clinically reasonable were included into the logistic model. The enter method was used to 
determine the effect of each factor in the presence of all other factors. Odds ratios and 95% 
confidence limits are reported.  All statistical data were analysed using SPSS (Version 12.0, 
SPSS, INC, Chicago, IL). The CONSORT guidelines were followed from the point of 
eligibility. Statistical results are all 2-tailed.  
PLACE FIGURE 1 HERE  
Results 
Between April 2004 and November 2004 we assessed 1,240 patients who were potentially 
eligible for the study. Amost half (n = 533) did not meet eligibility criteria and a further 501 
were excluded for other reasons (Fig 2). Table 1 shows the characteristics of the groups at 
baseline. Patients enrolled were mostly elderly and over half had at least 2 co-morbid medical 
conditions. Characteristics associated with  IV cannulation are shown in Table 2. There were 
no statistically significant differences between groups at baseline. 
PLACE TABLE 1AND TABLE 2 HERE 
Primary outcome 
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A total of 368 cannulas were inserted in the 206 participants. Forty six patients (44.6%) in the 
intervention group had an unplanned cannula removal compared with 41 (39.8%) in the 
control group [relative risk 1.12, 95% confidence interval 0.81 to 1.55 (p = 0.286)]. The total 
duration of peripheral cannulation was similar in both groups (mean 123.3 hours, SD 88.9 
hours in the intervention group and 125.9 hours, SD 73.0 hours in the control group: p = 0.82) 
but significantly more re-sites occurred in the control group (intervention group 103, control 
group 161: p = 0.022). Infiltration was the most frequent reason for removal (n = 89) and 
erythema the least frequent (n = 4).  Phlebitis was diagnosed on only 3 occasions, twice in the 
control group and once in the intervention group with each of these patients having a 
concurrent infection (one wound infection and two with cellulitis), they were all on antibiotic 
therapy and their cannulas had been in situ for an average of 48.7 hours (range 25 – 77 hours). 
Despite instructions in the study protocol, none of the cannula tips from these patients were 
sent for microbiological examination. There were no reported cases of bacteremia or local 
infection during the study.   
 
Secondary Outcome 
There was a significant difference in cost between the two groups (p = 0.006). The total cost 
of cannula changes for the 103 patients in the control group was AUD$3,837.56 compared 
with the total cost for the 103 patients in the intervention group of AUD$3,183.62. 
 
Other analysis 
When we combined all of the data a number of variables were associated with unplanned 
cannula removal, these are shown in Tables 3 and 4. When these variables were included in a 
logistic regression model, only frequency of cannula change (p = < 0.000), longer duration of 
cannulation (p = 0.008) and the irritability of IV medications other than antibiotics (p = 
0.042) remained statistically associated with unplanned cannula removal.  
PLACE TABLES 3 AND 4 HERE 
Discussion 
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Primary outcome 
The prospective randomised controlled design of the study has allowed us to compare the 
effects of re-siting intravenous peripheral cannulas when clinically indicated, with the 
standard practice of re-siting them every three days. Results show that outcomes are similar in 
both groups. This concurs with several other prospective, but not randomised studies in which 
the authors were unable to demonstrate any increased risk of phlebitis beyond the second day 
of cannulation (Bregenzer et al., 1998, Homer and Holmes, 1998). Conversely, our results are 
at odds with a recent randomised study where 42.3% of participants in a ‘change when 
clinically indicated group’ developed phlebitis compared with 4.8% in a 2-day change group 
(Barker et al., 2004). However there were a number of methodological flaws with that study. 
It was very small; only 47 participants were included with no indication of how the sample 
size was determined. In addition, the principal investigator, who was not blinded to group 
allocation, was responsible for classifying the outcome, providing a potential for reporting 
bias. Additionally, the phlebitis rate in the ‘change when clinically indicated group’ was much 
higher than those reported in well conducted clinical studies.  
 
 Secondary outcome 
Costings used in our study indicate that changing cannulas only when complications occur 
would reduce peripheral IV related expenditure by at least 17%. We project an annual cost 
benefit of approximately AUD $60,300 if cannulas re-sited by the IV Unit are replaced only 
when clinically indicated. Cost savings would be much higher if this policy were to be 
adopted in other areas of the hospital, where the IV Unit are not currently responsible for 
cannula changes.  Our estimates were very conservative, derived from the cost of a basic 
saline infusion and not including the cost of any other IV additives, IV analgesics or IV 
antibiotics, which may need replacing along with the re-site. In trials where there are no 
differences between intervention and control outcomes, the option with a lower cost should be 
chosen. In this case, the weight of evidence from recent studies along with our own findings 
indicates that the practice of routine 3-day peripheral cannula changes should be re-
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considered, at least in settings where well trained staff operating in an IV service exists. 
Further research is required to test if these benefits are sustained when a cannula is inserted 
by other hospital staff. 
 
Other outcomes 
None of the participants in the study developed bacteremia and our phlebitis rate for cannulas 
inserted by the IV Unit was extremely low at 1.5%. The revised Intravenous Nurses Society 
Standards of Practice states the incidence of peripheral vein infusion thrombophlebitis should 
be no more than 5% in any population (Anon, 2000) but most studies report higher rates 
(Chee and Tan, 2002, Martinez et al., 1994, White, 2001). Our low phlebitis rate prevents any 
meaningful correlations with risk factors but it was interesting to note that each of those with 
a documented phlebitis had a co-existing infection which was being treated with antibiotics. 
We could find only one other study reporting an association between phlebitis and an infected 
site remote from the cannula but, in that study, only 5.9% of potential sources of catheter 
related infections were attributed to a co-existing infection (Diener et al., 1996). However 
there is very good evidence from the infection control literature of the relationship between 
wound infection and remote site infections (Edwards, 1976) and this adds plausibility to the 
finding. Future research in the area should include information about existing infections.  
 
After adjustment, three risk factors remained associated with unplanned cannula removal in 
our study. Of these the total number of cannulas inserted during the period of hospitalisation 
was the most predictive. This was independent of the effect of the total cannulation period or 
any other risk factor. We also found that each of the participants who developed phlebitis did 
so within 77 hours of cannula insertion. Our finding is consistent with other investigators who 
have shown that the risk of phlebitis is highest on the second day after insertion and the day 
specific infection rate does not increase thereafter (Bregenzer et al., 1998, Homer and 
Holmes, 1998). This supports the notion that each time the skin integrity is broken there is a 
further opportunity for organisms to be introduced and cause local or systemic infection.  
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Taken together, results from recent studies, including our own, challenge the most recent 
recommendation for the prevention of intravascular catheter- related infections which states 
that “peripheral intravenous catheters should be replaced at least every 72-96 hours in adults 
to prevent phlebitis” (O'Grady et al., 2002).  When we reviewed the source of this 
recommendation we found that it was supported by only one study, published in 1998 and 
based on data collected in 1992 (Lai, 1998). It is at odds with recommendations for central 
venous catheters, peripheral arterial catheters or peripheral venous catheters in children where 
current guidelines read “Leave peripheral venous catheters in place in children until 
intravenous therapy is completed, unless complications (eg phlebitis and infiltration) 
occur.”(O'Grady et al., 2002) (p762).  In light of recent evidence, it is perhaps timely for 
guidelines recommending the frequency of changes in adults to be re-visited.  
 
Although a large number of patients were ineligible for the study, approximately half of these 
were because it was not anticipated that their cannula would remain in situ for more than 3 
days, or because the cannula had been in place for more than 48 hours before they were able 
to be enrolled. Neither of these reasons should have affected the results.  Of the other reasons 
for exclusion, having an existing blood stream infection, being immunosuppressed or being 
too ill to consent may impact on results being generalised. However, a large proportion of the 
patients we studied were quite elderly and many had a number of co-morbidities, making 
them a vulnerable but typical tertiary hospital population, so we believe our findings remain 
quite robust. A further study is about to commence in which patients excluded in the current 
study will be involved.  
 
Cannulation of peripheral veins is a painful yet necessary component of modern medical care. 
Frequent re-sites are distressing for patients, have a significant cost component and may lead 
to future venous access difficulties. The present study has shown that the risk of an adverse 
outcome is unaffected when cannulas are re-sited based on clinical parameters and not on 
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routine and that cost savings may be considerable if cannulas are re-sited only when clinically 
indicated. 
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Figure 1. Patient flow through the trial 
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Table 1 – Baseline characteristics of study participants  
 
 No-change 
(n=103) 
3-Day 
(n=103) 
 
P‡ 
Sex*  
Male 
             Female  
 
50 (48.5) 
53 (51.5) 
 
49 (47.6) 
54 (52.4) 
 
0.500 
 
Mean age in years† 60.22 [16.15] 63.06 [17.30] 0.225 
Reason for admission* 
 
Gastrointestinal 
Vascular 
Oncology 
Other 
 
49 (47.6) 
23 (22.3) 
12 (11.7) 
19 (18.4) 
 
47 (45.6) 
24 (23.3) 
12 (11.7) 
20 (19.4) 
 
0.993 
Past medical history* 
 
Nil 
1 co-morbid medical condition 
2 co-morbid medical conditions 
> 2 co-morbid medical conditions 
 
11 (10.7) 
27 (26.2) 
36 (35.0) 
29 (28.2) 
 
6 (5.8) 
28 (27.2) 
31 (30.1) 
38 (36.9) 
 
0.381 
Has current infection* 
 
Urinary tract 
Respiratory tract 
Wound/cellulitis 
 
2 (1.9) 
9 (8.7) 
20 (19.4) 
 
7 (6.8) 
9 (8.7) 
23 (22.3) 
 
0.085 
0.597 
0.366 
Type of surgery* 
 
             Nil 
Gastrointestinal 
 
46 (44.7) 
30 (29.1) 
 
41 (39.8) 
31 (30.1) 
 
0.913 
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Vascular 
Other 
> 1 operation 
13 (12.6) 
8 (7.8) 
6 (5.8) 
17 (16.5) 
7 (6.8) 
7 (6.8) 
Most recent Hb – mean ( g/dL ) †  
 
119.98 [19.08] 119.13 [17.04] 0.426 
Past history of phlebitis* 5 (4.9) 3 (2.9) 0.361 
Indwelling urinary catheter* 24 (23.3) 19 (18.4) 0.247 
 
* Results expressed as number and (percent) 
† Results presented as mean and [standard deviation] 
‡ Chi square for proportions or Student’s t test for continuous variables 
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Table 2. Infusion related characteristics of study participants   
 No-change 
(n=103) 
3-Day 
(n=103) 
P‡ 
IV cannula gauge* 
          20 gauge 
          22 gauge 
           Other 
 
61 (59.2) 
40 (38.8) 
  2 (1.9) 
 
59 (57.3) 
43 (41.7) 
  1 (1.0) 
 
0.789 
Vein assessment* 
          Poor 
          Fair/good 
 
39 (37.9) 
64 (62.1) 
 
43 (41.7) 
60 (58.3) 
 
0.335 
Receiving infusate* 82 (79.6) 81 (78.6) 0.500 
Mean irritability rating of infusate† 1.77 [0.92] 1.78 [0.91] 0.663 
Receiving IV antibiotics* 64 (62.1) 56 (54.4) 0.161 
Mean irritability rating of antibiotics† 2.51 [0.73] 2.34 [0.74] 0.615 
Receiving other IV medications* 70 (68.0) 68 (66.0) 0.441 
Mean irritability of IV medications† 1.42 [0.58] 1.41 [0.64] 0.845 
Insertion site of IV cannula* 
          All in hand 
          All in forearm 
          Combination of sites 
          Other 
 
26 (52.0) 
57 (57.0) 
17 (34.7) 
3 (42.9) 
 
24 (48.0) 
43 (43.0) 
32 (65.3) 
4 (57.1) 
 
0.079 
Other vascular device in situ* 21 (20.4) 18 (17.5) 0.361 
 
* Results expressed as number and (percent) 
† Results presented as mean and [standard deviation] 
‡ Chi square for proportions or Student’s t test for continuous variables 
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Table 3. General risk factors for unplanned cannula removal  
 Unplanned removal 
(n = 87) 
No unplanned removal 
(n = 119) 
 
P‡ 
Sex* 
Male 
Female 
 
35 (35.4) 
52 (48.6) 
 
64 (64.6) 
55 (51.4) 
 
0.067 
Mean age in years† 66.20 [14.37] 58.31 [17.61] 0.001 
Reason for admission* 
 
Gastrointestinal 
Vascular 
Oncology 
Other 
 
38 (39.6) 
26 (55.3) 
11 (45.8) 
12 (30.8) 
 
58 (60.4) 
21 (44.7) 
13 (54.2) 
27 (69.2) 
 
0.122 
Medical history* 
 
Nil 
1 co-morbid medical condition 
2 co-morbid medical conditions 
> 2 co-morbid medical conditions 
 
  6 (35.3) 
23 (41.8) 
28 (41.8) 
30 (44.8) 
 
11 (64.7) 
32 (58.2) 
39 (58.2) 
37 (55.2) 
 
0.914 
Urinary tract infection* 
 Yes 
 No 
Respiratory tract* 
               Yes 
               No 
Wound/cellulitis* 
               Yes 
               No 
 
  5 (55.6) 
82 (41.6) 
 
11 (61.1) 
76 (40.4) 
 
27 (62.8) 
60 (36.8) 
 
    4 (44.4) 
115 (58.4) 
 
    7 (38.9) 
112 (59.6) 
 
 16 (37.2) 
103 (63.2) 
 
0.498 
 
 
0.132 
 
 
0.003 
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Surgery* 
 
Yes 
No 
 
31 (35.6) 
56 (47.1) 
 
56 (64.4) 
63 (52.9) 
 
0.067 
Most recent Hb – mean ( g/dL )† 117.33 [17.24] 121.18 [18.50] 0.169 
Past history of phlebitis* 
          Yes 
          No 
 
4 (50.0) 
83 (41.9) 
 
4 (50.0) 
115 (58.1) 
 
0.458 
Indwelling urinary catheter* 
          Yes 
          No 
 
23 (53.5) 
64 (39.3) 
 
20 (46.5) 
99 (60.7) 
 
0.067 
 
* Results expressed as number and (percent) 
† Results presented as mean and [standard deviation] 
‡ Chi square for proportions or Student’s t test for continuous variables 
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Table 4. Infusion related risk factors for unplanned cannula removal.  
 Unplanned removal 
(n = 87) 
No unplanned removal 
(n = 119) 
P‡ 
IV cannula gauge* 
          20 gauge 
          22 gauge 
          Other 
 
44 (36.7) 
41 (49.4) 
 2 (66.7) 
 
76 (63.3) 
42 (50.6) 
1 (33.3) 
 
0.135 
Vein assessment* 
          Poor 
          Fair/good 
 
42 (51.2) 
45 (36.3) 
 
40 (48.8) 
79 (63.7) 
 
0.024 
Receiving infusate* 
          Yes 
          No 
 
70 (42.9) 
17 (39.5) 
 
93 (57.1) 
26 (60.5) 
 
0.411 
Mean irritability rating of IV infusate† 1.72 [0.87] 1.81 [0.95] 0.531 
Receiving IV antibiotics* 
          Yes 
          No 
 
59 (49.2) 
28 (32.6) 
 
61 (50.8) 
58 (67.4) 
 
0.012 
Mean irritability rating of antibiotics† 2.34 (0.74) 2.52 [0.72] 0.166 
Receiving other IV medications* 
          Yes 
          No 
 
63 (45.7) 
24 (35.3) 
 
75 (54.3) 
44 (64.7) 
 
0.102 
Mean irritability of IV medications† 1.55 [0.56] 1.31 [0.63] 0.024 
Insertion site of IV cannula* 
Only in hand or wrist 
Only in arm (includes cubital fossa) 
Combination of sites 
 
13 (25.5) 
37 (34.9) 
37 (75.5)   
 
38 (74.5) 
63 (65.1) 
12 (24.5) 
 
0.000 
Mean number of cannulas† 2.52 [1.07] 1.26 [0.57] 0.000 
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Other vascular device in situ* 
          Yes 
          No 
 
24 (61.5) 
63 (37.7) 
 
15 (38.5) 
104 (62.3) 
 
0.006 
Total duration of cannulation† 160.36 [95.97] 98.5 [55.67] 0.000 
 
* Results expressed as number and (percent) 
† Results presented as mean and [standard deviation] 
‡ Chi square for proportions or Student’s t test for continuous variables 
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Table 5. Adjusted risk factors associated with unplanned cannula removal among 
hospital patients 
 Crude OR* 95% CI† Adjusted OR 95%CI 
Age (years) 0.97 0.95-0.99 0.99 0.97-1.03 
Vein assessment 
   Fair/good 
   Poor 
 
1 
0.54 
 
 
0.31-0.96
 
 
0.47 
 
 
0.18-1.26 
IV antibiotics 0.50 0.28-0.88 1.05 0.38-2.87 
Cannula insertion site 
   Only in hand or wrist 
   Only in arm or cubital fossa 
   Multiple sites 
 
1 
0.64 
0.11 
 
 
0.30-1.35
0.45-0.27
 
1 
0.69 
0.88 
 
 
0.21-2.28 
0.18-4.33 
Mean number of cannulas 0.12 0.07-0.22 0.08 0.03-0.22‡
Other vascular device in situ 
   No 
   Yes 
 
1 
0.38 
 
 
0.19-0.77
 
1 
0.43 
 
 
0.12-1.49 
Total duration of cannulation 0.99 0.98-0.99 1.01 1.00-1.02‡ 
Mean irritability of  IV  
medications (other than IV 
antibiotics) 
0.52 0.29-0.93 0.45 0.21-0.97‡ 
 
* OR = odds ratio 
† CI  = 95% confidence interval. 
‡ Statistically associated with unplanned cannula removal 
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